DESIGN OF BETA CELL LYMPHOMA-2 (BCL-2) RECEPTOR ANTAGONISTS AS CHEMOTHERAPEUTIC AGENTS
- At: 2019 FIP Congress in AbuDhabi (United Arab Emirates)
- Type: Poster
- By: SHOEMAKE, Claire (University of Malta, Pharmacy, Malta)
- Co-author(s): Yvonne Savona Ventura: Pharmacy, University of Malta, Msida, Malta
Claire Shoemake: Pharmacy, University of Malta, Msida, Malta
The Beta Cell Lymphoma-2 (BCL-2) receptor is a prosurvival protein. It is consequently a target in the design of molecules capable of restoring cells' to perform apoptosis. Navitoclax and venetoclax are BCL-2 antagonists, but are associated with thrombocytopaenic side-effects.
A virtual screening approach was adopted. Bioactive.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.